introduct
surfact
protein
spd
play
import
role
innat
respons
pathogen
product
alter
lung
disord
method
studi
circul
level
spd
patient
acut
respiratori
distress
syndrom
due
viru
infect
healthi
control
cox
logist
regress
model
construct
explor
associ
spd
level
risk
death
result
mortal
rate
signific
higher
level
spd
detect
patient
fatal
outcom
p
adjust
confound
variabl
level
spd
ngml
associ
increas
risk
death
hr
ci
p
conclus
result
reveal
higher
circul
level
spd
associ
higher
mortal
risk
critic
ill
patient
spd
might
predict
factor
poor
outcom
viral
pneumonia
host
factor
includ
cardiac
respiratori
metabol
comorbid
associ
poorer
outcom
infect
develop
acut
respiratori
distress
syndrom
ard
recent
studi
support
hypothesi
dysregul
immun
activ
key
factor
determin
develop
sever
pneumonia
surfact
protein
spd
synthes
type
ii
pneumocyt
belong
collectin
famili
main
function
recogn
pathogen
associ
molecular
pattern
allow
microbi
elimin
spd
particip
neutral
clearanc
influenza
virus
given
molecular
affin
viral
hemagglutinin
spd
level
correl
proinflammatori
immun
respons
mainli
alveolar
macrophag
interact
trimer
form
trough
receptor
lead
activ
mapk
signal
pathway
elicit
respons
spd
product
influenc
divers
lung
disord
role
biomark
lung
inflamm
describ
base
central
role
spd
pulmonari
host
defens
regul
inflammatori
respons
dysregul
lung
diseas
hypothes
circul
level
spd
modifi
result
lung
tissu
damag
critic
ill
patient
spd
use
biomark
predict
poor
outcom
ard
patient
infect
aim
determin
circul
level
spd
correl
risk
mortal
followup
critic
ill
patient
infect
diagnosi
infect
assess
presenc
influenzalik
symptom
bilater
pulmonari
infiltr
posit
test
rtpcr
viru
diagnosi
ard
base
standard
definit
group
asymptomat
household
contact
close
contact
patient
develop
acut
respiratori
diseas
recruit
importantli
contact
exhibit
signific
titer
antibodi
support
fact
contact
viru
institut
review
board
iner
review
approv
studi
subject
legal
author
rel
provid
written
inform
consent
nasopharyng
sampl
obtain
viral
rna
isol
use
viral
rnamini
kit
qiagen
westburg
leusden
netherland
detect
viru
assess
real
time
rtpcr
circul
level
spd
measur
elisa
biovendor
research
product
elisa
kit
ashervil
nc
usa
briefli
serum
standard
incub
h
antispd
antibodi
three
wash
hrp
solut
ad
incub
h
onehundr
microlit
tmb
substrat
ad
well
reaction
stop
min
ad
stop
solut
absorb
nm
measur
micropl
elisa
reader
biorad
laboratori
inc
ca
usa
titer
serum
antibodi
measur
use
hemagglutin
inhibit
hai
assay
briefli
serial
dilut
serum
sampl
ml
mix
ml
viru
strain
serumviru
dilut
incub
min
room
temperatur
fifti
millilit
chicken
erythrocyt
ad
min
hai
activ
evalu
serum
antibodi
titer
establish
reciproc
last
serum
dilut
hemagglutin
activ
titer
greater
consid
posit
demograph
characterist
vital
sign
clinic
outcom
treatment
mechan
ventil
ga
exchang
paramet
laboratori
test
apach
ii
score
determin
admiss
icu
continu
variabl
compar
use
student
test
variabl
normal
distribut
mannwhitney
u
test
otherwis
categor
variabl
analyz
use
v
test
cox
multivari
proport
hazard
model
construct
explor
factor
associ
risk
death
independ
variabl
test
model
demograph
anthropometr
data
lung
function
laboratori
find
comorbid
condit
chose
cutoff
ngml
determin
two
group
surviv
analysi
cutoff
arbitrarili
select
extens
review
literatur
found
gener
serum
level
spd
healthi
volunt
typic
lower
ngml
addit
certain
patholog
condit
idiopath
pulmonari
fibrosi
copd
interstiti
pneumonia
serum
mean
level
spd
usual
higher
ngml
correl
spd
level
bmi
assess
use
spearman
correl
coeffici
signific
level
set
twotail
p
p
case
multipl
comparison
analys
perform
use
stata
v
statacorp
colleg
station
tx
usa
clinic
demograph
characterist
patient
present
tabl
median
age
studi
patient
asymptomat
control
similar
twentythre
patient
male
current
former
smoker
signific
differ
detect
bodi
mass
index
bmi
eightynin
percent
patient
requir
invas
mechan
ventil
due
respiratori
failur
defin
pao
valu
mmhg
normal
valu
altitud
mexico
citi
mmhg
despit
fio
increas
breath
effort
accessori
respiratori
muscl
usag
mortal
rate
followup
patient
main
sign
symptom
start
ill
includ
fever
myalgia
cough
headach
chest
pain
dyspnea
cyanosi
occur
usual
third
day
patient
treat
oseltamivir
mgday
period
requir
mechan
ventil
addit
patient
receiv
ceftriaxon
clarithromycin
time
admiss
treatment
sustain
patient
mechan
ventil
upgrad
case
fever
leukocytosi
develop
new
infiltr
chest
xray
appear
antibiot
resist
document
sampl
bronchial
aspir
blood
urin
bronchial
secret
cultur
perform
time
hospit
icu
reveal
neither
bacteri
fungal
mycobacteri
secondari
infect
system
corticosteroid
administ
patient
dose
mgkgday
methylprednisolon
mechan
ventil
period
clinic
biochem
variabl
includ
apach
ii
score
show
signific
differ
among
subgroup
fatal
outcom
critic
ill
patient
associ
increas
level
circul
spd
illustr
tabl
fig
circul
spd
valu
significantli
higher
patient
die
ngml
compar
survivor
ngml
p
healthi
control
ngml
p
adjust
confound
variabl
includ
age
gender
pao
fio
found
serum
spd
concentr
ng
ml
significantli
increas
risk
death
studi
popul
hr
ci
p
addit
kaplanmei
surviv
estim
calcul
refer
valu
patient
spd
concentr
ngml
show
surviv
estim
ci
meanwhil
probabl
ci
ngml
group
p
fig
signific
correl
spd
level
bmi
detect
among
mani
effect
spd
shown
strong
chemoattract
monocyt
neutrophil
import
effect
pathogenesi
lung
disord
studi
analyz
circul
level
spd
mainli
secret
alveoli
thu
rise
serum
concentr
may
reflect
protein
transloc
caus
abnorm
increas
alveolarcapillari
membran
permeabl
possibl
due
loss
structur
integr
serum
spd
propos
biomark
acut
chronic
respiratori
diseas
includ
copd
ipf
divers
clinic
studi
studi
support
hypothesi
potenti
deleteri
effect
overproduct
spd
directli
associ
wors
clinic
outcom
lung
diseas
nishida
cowork
report
nonsignific
correl
spd
mucin
level
clinic
progress
poorer
outcom
pediatr
patient
differ
might
explain
pediatr
patient
milder
diseas
requir
mechan
ventil
wherea
patient
requir
mechan
ventil
icu
interestingli
studi
describ
low
level
spd
express
lung
associ
fatal
influenza
strain
find
indic
serum
spd
level
might
use
estim
risk
poorer
outcom
critic
patient
sever
lung
diseas
associ
well
document
spd
glycoprotein
involv
regul
innat
immun
antivir
respons
lung
protein
often
transloc
system
circul
clinic
condit
lung
permeabl
increas
differ
studi
demonstr
spa
spd
import
biomark
ipf
high
level
surfact
protein
predictor
mortal
addit
evid
larg
cohort
also
support
import
prognost
marker
clinic
exacerb
copd
progress
recent
report
suggest
analysi
circul
level
spd
use
diagnost
tool
sever
sepsi
patient
ard
evalu
progress
lung
injuri
critic
ill
patient
mechan
ventil
circul
level
protein
posit
correl
lung
injuri
score
paramet
measur
pathophysiolog
featur
ard
scenario
clinic
experiment
studi
demonstr
increas
plasma
spd
level
could
reflect
acut
alveolar
damag
type
ii
cell
hyperplasia
thu
spd
level
appear
reliabl
indic
alter
alveolar
epitheli
permeabl
hydrophil
surfact
protein
spa
possibl
result
higher
capac
enter
circul
spd
play
critic
role
regul
macrophag
neutrophil
fibrocyt
infiltr
promot
product
proinflammatori
profibrot
cytokin
includ
tgfb
pdgfaa
viral
lung
infect
spd
may
particip
recruit
macrophag
contribut
dysregul
inflammatori
respons
critic
ill
patient
nonregul
inflammatori
respons
may
exert
deleteri
effect
lung
tissu
result
develop
sever
diseas
investig
report
higher
level
proinflammatori
mediat
includ
serum
bronchoalveolar
lavag
patient
sever
pneumonia
either
household
contact
healthi
control
corticosteroid
treatment
may
help
reduc
circul
lung
level
proinflammatori
mediat
howev
recent
report
demonstr
earli
use
corticosteroid
therapi
reduc
mortal
critic
ill
patient
influenza
viru
infect
contrast
corticosteroid
treatment
significantli
decreas
lung
injuri
mortal
patient
sever
infect
septic
shock
studi
dose
mgkgday
methylprednisolon
administ
icu
admit
patient
mechan
ventil
outbreak
april
mention
result
section
mortal
rate
observ
patient
day
wherea
mortal
observ
patient
receiv
similar
dose
steroid
day
followup
possibl
use
corticosteroid
therapi
may
result
increas
suscept
secondari
bacteri
infect
due
pronounc
reduct
protect
immun
mediat
studi
limit
includ
rel
small
number
patient
studi
sampl
size
restrict
studi
focu
critic
ill
patient
short
durat
outbreak
moreov
choos
includ
patient
influenzalik
ill
like
associ
infect
without
viral
corrobor
second
limit
inabl
includ
replic
cohort
patient
ard
associ
respiratori
virus
differ
strain
third
lack
experiment
assay
understand
possibl
role
spd
pathogenesi
sever
infect
summari
result
indic
higher
circul
level
spd
associ
higher
mortal
risk
patient
pneumonia
due
viru
protein
potenti
prognost
biomark
poorer
outcom
viral
pneumonia
work
necessari
identifi
mechan
determin
possibl
pathogen
effect
high
level
spd
infect
lung
